Cargando…

Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients

BACKGROUND AND OBJECTIVES: A quantitative evaluation of the PK of meropenem, a broad-spectrum β-lactam antibiotic, in plasma and interstitial space fluid (ISF) of subcutaneous adipose tissue of obese patients is lacking as of date. The objective of this study was the characterisation of meropenem po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Busse, David, Simon, Philipp, Schmitt, Lisa, Petroff, David, Dorn, Christoph, Dietrich, Arne, Zeitlinger, Markus, Huisinga, Wilhelm, Michelet, Robin, Wrigge, Hermann, Kloft, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095536/ https://www.ncbi.nlm.nih.gov/pubmed/34894344 http://dx.doi.org/10.1007/s40262-021-01070-6

Ejemplares similares

Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics
por: Busse, David, et al.
Publicado: (2021)

Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients—A Controlled Clinical Trial
por: Simon, Philipp, et al.
Publicado: (2020)

Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis
por: Dorn, Christoph, et al.
Publicado: (2022)

Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study
por: Simon, Philipp, et al.
Publicado: (2020)

Measurement of soft tissue drug concentrations in morbidly obese and non-obese patients – A prospective, parallel group, open-labeled, controlled, phase IV, single center clinical trial()
por: Simon, P., et al.
Publicado: (2019)

Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
por: Busse, David, et al.
Publicado: (2021)

Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data
por: Kluwe, Franziska, et al.
Publicado: (2023)

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients
por: Liebchen, Uwe, et al.
Publicado: (2021)

Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools
por: Weinelt, Ferdinand Anton, et al.
Publicado: (2022)

Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion
por: Nassar, Yomna M., et al.
Publicado: (2022)

Meropenem: continuous or extended infusion?
por: Frippiat, Frédéric, et al.
Publicado: (2020)

Cell‐level systems biology model to study inflammatory bowel diseases and their treatment options
por: Stübler, Sabine, et al.
Publicado: (2023)

Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study
por: Ehmann, Lisa, et al.
Publicado: (2017)

Microdialysis of Voriconazole and its N-Oxide Metabolite: Amalgamating Knowledge of Distribution and Metabolism Processes in Humans
por: Schulz, Josefine, et al.
Publicado: (2022)

Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide
por: Schulz, Josefine, et al.
Publicado: (2022)

An investigation of the stability of meropenem in elastomeric infusion devices
por: Foy, Finbarr, et al.
Publicado: (2019)

Meropenem administration by intermittent infusion versus continuous infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2005)

Deriving mechanism‐based pharmacodynamic models by reducing quantitative systems pharmacology models: An application to warfarin
por: Falkenhagen, Undine, et al.
Publicado: (2023)

Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
por: Grensemann, Jörn, et al.
Publicado: (2020)

Exploring Dried Blood Spot Cortisol Concentrations as an Alternative for Monitoring Pediatric Adrenal Insufficiency Patients: A Model-Based Analysis
por: Stachanow, Viktoria, et al.
Publicado: (2022)

Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis
por: Krippendorff, Ben-Fillippo, et al.
Publicado: (2009)

Continuous infusion of meropenem in critically ill patients: practical considerations
por: Taccone, Fabio Silvio
Publicado: (2012)

Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing—A Translational Example for Intensive Care Units
por: Weinelt, Ferdinand Anton, et al.
Publicado: (2021)

Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
por: Michelet, Robin, et al.
Publicado: (2023)

Comparison of the Effectiveness of Prolonged Infusion and Intermittent Infusion of Meropenem in Patients With Sepsis: A Meta-Analysis
por: Lokhandwala, Adnan, et al.
Publicado: (2023)

Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa
por: Nussbaumer-Pröll, A., et al.
Publicado: (2022)

C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework
por: Nassar, Yomna M., et al.
Publicado: (2023)

Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability
por: Manning, Laurens, et al.
Publicado: (2014)

Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study
por: Cao, Guangna, et al.
Publicado: (2022)

1547. Modeling Pharmacokinetics and Pharmacodynamics of Meropenem Utilizing a Novel Infusion Method of Bolus to Prolonged Infusion
por: Moore, Sarah E, et al.
Publicado: (2019)

Bayesian Data Assimilation to Support Informed Decision Making in Individualized Chemotherapy
por: Maier, Corinna, et al.
Publicado: (2020)

Reinforcement learning and Bayesian data assimilation for model‐informed precision dosing in oncology
por: Maier, Corinna, et al.
Publicado: (2021)

A continued learning approach for model‐informed precision dosing: Updating models in clinical practice
por: Maier, Corinna, et al.
Publicado: (2021)

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review
por: Démaris, Alix, et al.
Publicado: (2022)

Sleep Duration and Obesity
por: Kim, JungHwan
Publicado: (2017)

Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
por: Pařízková, Renata Černá, et al.
Publicado: (2021)

Therapeutic drug monitoring of meropenem and piperacilin administered in continuous infusion. preliminary data
por: Miralbés Torner, M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_935nk7k2t1u1ugpkdklah9nnrf